The positive results from the Phase 3 ORCA-3 trial of cytisinicline indicate a significant benefit in helping people quit smoking compared to placebo. This could lead to regulatory approval and commercialization of the drug, potentially increasing Achieve Life Sciences' revenues and boosting its stock price in the short term.